Clear Street’s Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 CLDI.WS Stock Holding History

Clear Street’s Portfolio CLDI.WS Stock Details CLDI.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-6,617	Closed	-$87	–	764
2024 Q3	$87	Buy	6,617 +4,871	+279%	+$149	﹤0.01%	667
2024 Q2	$74	Hold	1,746	–	–	﹤0.01%	745
2024 Q1	$91	Hold	1,746	–	–	﹤0.01%	739
2023 Q4	$87	Sell	1,746 -200	-10%	-$23	﹤0.01%	766
2023 Q3	$428	Buy	+1,946	New	+$356	﹤0.01%	958
2023 Q1	–	Sell	-100	Closed	–	–	1295
2022 Q4	$0	Hold	100	–	–	﹤0.01%	1226
2022 Q3	$0	Hold	100	–	–	﹤0.01%	1274
2022 Q2	$0	Buy	+100	New	+$22	﹤0.01%	1075

Other funds holding CLDI.WS

EAM

Exos Asset Management New York $2.32K AUM 108.13% 1-Year Est. Return

Clear Street's CLDI.WS Position: Q4 2024 in Review

Clear Street sold out of Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 (CLDI.WS) in Q4 2024, closing a stake of 6,617 shares — an estimated $87 sold.

Clear Street first reported a position in CLDI.WS in Q2 2022 and held it in 8 quarters. The position peaked at $428 in Q3 2023. 1 fund tracked by Wall St. Rank holds CLDI.WS as of Q4 2024.

Clear Street reported no remaining Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 position as of Q4 2024 after selling out during the quarter.
Clear Street sold 6,617 Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 shares in Q4 2024, an estimated $87.
Clear Street first reported a position in Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 in Q2 2022 and held it in 8 quarters.
Clear Street's Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 position peaked at $428 in Q3 2023.
1 fund tracked by Wall St. Rank held Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 as of Q4 2024.

Based on Clear Street's 13F filing for Q4 2024, filed 14 Feb 2025.